NGEN — NERVGEN PHARMA CORP.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1751912 ·
Last close
$1.88
Market Cap
$202.14M
52W High
$6.30
52W Low
$1.58
ADV30
574,900
Next earnings
2026-11-23
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,196,618 | -29,217,233 | 90,190,914 | 86,789,698 | 72,913,623 |
| Mar 2026 | 0 | — | -7,531,578 | -1,675,549 | — | — | — |
| Dec 2025 | 0 | — | -6,404,283 | -26,908,856 | 23,209,641 | 22,069,635 | 19,732,715 |
| Sep 2025 | 0 | — | -6,170,687 | -4,156,070 | 13,077,452 | 11,364,055 | 16,019,155 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,499,211
Investing CF
$100,926
Financing CF
$23,763,937
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.34
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-146,763,518
Inventory
—
Receivables
$80,825
ST Investments
$8,369
EBIT TTM
$-26,575,548
Pretax Income TTM
$-41,844,662
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -25,079,252 | -44,117,305 | 23,209,641 | 19,732,715 | 3,476,926 | -19,499,211 |
| Dec 2024 | 0 | -25,176,149 | -24,250,049 | 19,486,223 | 16,909,616 | 2,576,607 | -16,841,034 |
| Dec 2023 | 0 | -17,776,710 | -22,382,120 | 13,236,021 | 15,245,126 | -2,009,105 | -11,295,594 |
| Dec 2022 | 0 | -23,025,033 | -20,722,283 | 23,875,217 | 10,414,137 | 13,461,080 | -17,784,163 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $1.88 · call oi: 2,663 · put oi: 169
Expected Move to 2026-11-20:
±$1.18
(62.50%) —
implied range
$0.70 –
$3.05
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | $199.41M | $27.45 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $197.59M | $4.75 | — |
| FHTX | Foghorn Therapeutics Inc. | $209.04M | $3.52 | — |
| VRXA | Veraxa Biotech AG - Post de-SPAC | $193.73M | $1.37 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $192.21M | $1.39 | — |
News headlines (Yahoo Finance, 1h cache)
NervGen to Host Inaugural R&D Day on September 30, 2026
2026-09-09 11:30 · Yahoo
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 11:30 · Yahoo
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
2026-05-26 11:15 · Yahoo
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
2026-05-22 03:27 · Yahoo
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-18 11:15 · Yahoo
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
2026-09-25 20:30 · Yahoo
NervGen Announces Proposed Public Offering of Securities
2026-05-21 20:01 · Yahoo
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
2026-04-27 11:30 · Yahoo
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-13 11:45 · Yahoo
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
2026-04-07 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.